Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 2376901 trials

ST PHARM CO., LTD.

Official website

ST Pharm operates a top-3 global oligonucleotide CDMO and develops in-house drug candidates including the HIV treatment STP0404.

As of 2026-10-10, ST PHARM CO., LTD. has 29 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2008, ST Pharm listed on KOSDAQ in 2016 as an API and CDMO company. It holds the No.1 position in Asia and a top-3 global position in oligonucleotide (RNA therapeutic raw material) CDMO, also operates small-molecule CDMO and generic CMO businesses, and is the only global CDMO to hold US FDA cGMP certification in both small-molecule (2018) and oligonucleotide (2022) API manufacturing. Its in-house pipeline includes the first-in-class HIV treatment STP0404 (Pirmitegravir, in US Phase 2a trials) and the anticancer drug STP1002 (Basroparib, Phase 1 completed) for advanced solid tumors, and it has signed a KRW 17.7 billion LNP lipid supply agreement with a North American mRNA drug developer (2022) and a strategic partnership with Germany's Evonik Industries (2025).

Products & technology

  • Oligonucleotide APICDMO for RNA therapeutic raw material
  • Small-molecule API CDMOContract development and manufacturing of small-molecule APIs
  • Generic CMOContract manufacturing for generics
  • sgRNA raw materialCDMO for CRISPR-Cas9-related gene editing raw materials

Clinical trials

data.go.kr

1 MFDS clinical trial authorisations · 2022 (Phase 1 1)

  • Phase 1STP2104 주2022-03-24

    8 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

STP0404(Pirmitegravir) · 에이즈(HIV) 치료제 · 미국 임상 2a상 진행 중(프랑스 임상1상 완료) · First-in-class drug in its class to enter human trials. Cohort 1/2 interim results presented at IDWeek in Oct. 2025; final Phase 2a data including cohort 3 planned for 2026

STP1002(Basroparib) · 대장암, 비소세포폐암, 간암 등 진행성고형암 · 임상1상 완료 · First-in-class anticancer drug; Phase 1 results disclosed Sep. 2024 showing safety, presented at ESMO Congress 2024 (Sep 13-17, 2024)

Key disclosures

KRX KIND via OpenDART
Show 2 more events

Publications

PubMed · affiliation-matched
Show 19 more publications

Patents

KIPRIS · applicant-matched
Show 163 more patents

AI reads

MAA server logs · IP-verified
81
Times AI engines pulled ST PHARM CO., LTD.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

13
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

68
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

15
live 1
Last 7 days
71
live 13
Last 30 days
81
live 13
All time
  • OpenAIChatGPT-Userlive13
  • OpenAIOAI-SearchBot60
  • PerplexityPerplexityBot5
  • AnthropicClaudeBot2
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for ST PHARM CO., LTD. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition